← Leaderboards
Charles Arthur Peloquin
University Of Colorado Denver
$2,074,443
Attributed
$2,074,443
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $430.2K · FY2016–20$500K$375K$250K$125K$0
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$2,074,443 · 2
By mechanism
P01$1,660,737 · 1
M01$413,706 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Stanley J Szefler$16,550,328
- Michael T Lewis$21,208,742
- Kevin J. Staley$35,882,339
- Donald Ym Leung$75,548,590
- Marian J. Rewers$53,889,410
Others in their field
Top investigators on “Tuberculosis”
- Judith S. Currier · University Of California Los Angeles$301,722,065
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$297,204,160
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$267,912,117
- Lawrence Corey · Fred Hutchinson Cancer Center$255,939,398
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$200,192,298
- Sharon A Nachman · Johns Hopkins University$194,852,226
Research focus
TuberculosisRespiratory Disorder ChemotherapyHigh Performance Liquid ChromatographyAntitubercular AgentsClinical TrialsIntravenous AdministrationPharmacokineticsDrug Screening /EvaluationClinical ResearchHuman Therapy EvaluationHuman SubjectGas ChromatographyCommunicable DiseasesCombined Modality TherapyAmericanCollegeAssay DevelopmentDrug KineticsClia CertifiedFiberEquipmentAnimalsGood Laboratory PracticeEpithelial
Grant awards (10)
Assay Core$313,924
P01 · FY2020 · AI · contact PI
Assay Core$306,671
P01 · FY2019 · AI · contact PI
Assay Core$304,567
P01 · FY2018 · AI · contact PI
Assay Core$305,352
P01 · FY2017 · AI · contact PI
Assay Core$430,223
P01 · FY2016 · AI · contact PI
PHARMACOKINETICS OF THE ANTITUBERCULOSIS DRUGS$190,747
M01 · FY2002 · RR
PHARMACOKINETICS OF THE ANTITUBERCULOSIS DRUGS$190,747
M01 · FY2001 · RR
PHARMACOKINETICS OF THE ANTITUBERCULOSIS DRUGS$0
M01 · FY2001 · RR
PHARMACOKINETICS OF THE ANTITUBERCULOSIS DRUGS$32,212
M01 · FY2000 · RR
PHARMACOKINETICS OF THE ANTITUBERCULOSIS DRUGS$0
M01 · FY2000 · RR